Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Rami Manochakian, Kena C. Miller, Asher Chanan‐Khan
The Oncologist, 2007
Abstract
This research paper explore the methodology and findings associated with The Oncologist. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
Related Research
- Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma 2012
- Three cases of bortezomib-resistant multiple myeloma with extramedullary masses. 2010
- Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma 2007
- Proteasome Inhibitors in Treatment of Multiple Myeloma 2013
- Effect of Bortezomib on serum cystatin-C in multiple myeloma 2011
References
- Cancer incidence and mortality in Europe 1989
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities 2000
- Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis 2001
- Regulation of NF-kB in multiple myeloma: therapeutic implications. 2004
- A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma. 2006